Skip to main content
Top
Published in: Cancer Causes & Control 3/2009

01-04-2009 | Original Paper

Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer

Authors: Jennifer H. Martin, M. D. Coory, P. C. Valery, A. C. Green

Published in: Cancer Causes & Control | Issue 3/2009

Login to get access

Abstract

Background

The association between diabetes and cancer incidence has been well documented, but relatively little research has been undertaken on the potential influence of diabetes on cancer survival and the research that is available has produced inconsistent results. Because Indigenous Australians have a high prevalence of diabetes, we assessed survival, stratified by diabetes, among Indigenous Australian cancer patients. We also assessed survival, stratified by diabetes, amongst a cohort of non-Indigenous Australian cancer patients.

Methods

All-cause survival and cancer-specific survival in diabetic versus non-diabetic cancer patients were assessed in Indigenous and non-Indigenous cohorts separately, using proportional hazards models.

Findings

Indigenous cancer patients with diabetes (n = 140) had an overall survival disadvantage compared to Indigenous cancer patients without diabetes (n = 675) with all-cause Hazard Ratio (HR) = 1.4 (95% CI 1.1–1.8) adjusted for age, sex, and cancer site. After further adjustment to take into account the greater number of non-cancer deaths and co-morbidities in Indigenous cancer patients with diabetes, and their later stage at cancer diagnosis with less cancer treatment, there was no residual difference in cancer-specific survival compared to Indigenous cancer patients without diabetes (cancer-specific HR = 1.0, 95% CI 0.8, 1.3). Fewer non-Indigenous cancer patients had diabetes (n = 52) and they showed no differences in survival compared to their counterparts without diabetes.

Interpretation

The poorer survival of Indigenous Australian cancer patients with diabetes was due to more non-cancer deaths, later stage at cancer diagnosis, less cancer treatment, and more co-morbidities than Indigenous Australian cancer patients without diabetes. In contrast, diabetes did not appear to affect survival in non-Indigenous Australians with cancer, either because there were too few to detect a moderate deleterious effect or because there was no association. Understanding the relation between diabetes and cancer treatment and survival is important because both diabetes and cancer are relatively common diseases, increasingly likely to co-exist.
Literature
2.
go back to reference Toyoda H, Kumada T, Nakano S (2001) Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 91:957–963. doi:10.1002/1097-0142(20010301)91:5<957::AID-CNCR1085>3.0.CO;2-J Toyoda H, Kumada T, Nakano S (2001) Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 91:957–963. doi:10.1002/1097-0142(20010301)91:5<957::AID-CNCR1085>3.0.CO;2-J
7.
go back to reference Little S, Jarnagin W, DeMatteo R, Blumgart L, Fong Y (2002) Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 6:88–94. doi:10.1016/S1091-255X(01)00019-1 PubMedCrossRef Little S, Jarnagin W, DeMatteo R, Blumgart L, Fong Y (2002) Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 6:88–94. doi:10.​1016/​S1091-255X(01)00019-1 PubMedCrossRef
10.
go back to reference Australian Bureau of Statistics, Australian Institute of Health, Welfare (2005) The Health and Welfare of Australia’s Aboriginal and Torres Strait Islander Peoples. ABS, Canberra Australian Bureau of Statistics, Australian Institute of Health, Welfare (2005) The Health and Welfare of Australia’s Aboriginal and Torres Strait Islander Peoples. ABS, Canberra
12.
go back to reference Surveillance Epidemiology End Results (2001) Summary staging manual 2000: codes and coding instructions. National Cancer Institute, Bethesda Surveillance Epidemiology End Results (2001) Summary staging manual 2000: codes and coding instructions. National Cancer Institute, Bethesda
13.
go back to reference McKinnon P, Reichley R, Noirot L, Dunagan W, Bailey T.(2006) Prospective validation of an algorithm to identify hospitalized diabetic patients using administrative data. AMIA Annu Symp Proc 1029 (PMID 17238648) McKinnon P, Reichley R, Noirot L, Dunagan W, Bailey T.(2006) Prospective validation of an algorithm to identify hospitalized diabetic patients using administrative data. AMIA Annu Symp Proc 1029 (PMID 17238648)
14.
go back to reference Steiner E, Eicher O, Sagemuller J, Schmidt M, Pilch H, Tanner B (2003) Multivariate independent prognostic factors in endometrial carcinoma: a clinopathologic study in 1881 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 13:197–203. doi:10.1046/j.1525-1438.2003.13021.x PubMedCrossRef Steiner E, Eicher O, Sagemuller J, Schmidt M, Pilch H, Tanner B (2003) Multivariate independent prognostic factors in endometrial carcinoma: a clinopathologic study in 1881 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 13:197–203. doi:10.​1046/​j.​1525-1438.​2003.​13021.​x PubMedCrossRef
15.
go back to reference Kaupplia A, Gronroos M, Nieminen U (1982) Clinical outcome in endometrial cancer. Obstet Gynecol 60:473–480 Kaupplia A, Gronroos M, Nieminen U (1982) Clinical outcome in endometrial cancer. Obstet Gynecol 60:473–480
16.
go back to reference Weiser M et al (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone/methotrexate-cytarabine regimen. Cancer 100:1179–1185. doi:10.1002/cncr.20071 PubMedCrossRef Weiser M et al (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone/methotrexate-cytarabine regimen. Cancer 100:1179–1185. doi:10.​1002/​cncr.​20071 PubMedCrossRef
17.
go back to reference Palanivel R, Maida A, Liu Y, Sweeny G (2006) Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetalogia 49(1):183–190. doi:10.1007/s00125-005-0060-z CrossRef Palanivel R, Maida A, Liu Y, Sweeny G (2006) Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetalogia 49(1):183–190. doi:10.​1007/​s00125-005-0060-z CrossRef
18.
go back to reference Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A et al (2001) Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7:928–934PubMed Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A et al (2001) Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7:928–934PubMed
Metadata
Title
Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer
Authors
Jennifer H. Martin
M. D. Coory
P. C. Valery
A. C. Green
Publication date
01-04-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 3/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9249-z

Other articles of this Issue 3/2009

Cancer Causes & Control 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine